Live Analyst Rating Changes 3234 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matthew Biegler
OPCO
Matthew Biegler
Oppenheimer
Wall Street Analyst
★☆☆☆☆
#2372
on 13Foresight · ranked by our own returns
34%
Success Rate
-3.0%
Average Return
12 of 35 calls profitable · -96.5% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 34% of Matthew Biegler's ratings turned a profit when each position was held for 1 year — averaging -3.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

94 Buy 23 Hold 0 Sell
Matthew's Stock Coverage 29 ratings · 2026-06-26
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
GILD
Gilead Sciences
 Jun 15, 2026 HOLD Strong Buy
-5.1% avg upside
66 analysts
 — -0.4%
OLMA
Olema Pharmaceuticals
 Jun 15, 2026 HOLD Strong Buy
+238.0% avg upside
16 analysts
 — +12.8%
RLAY
Relay Therapeutics
 Jun 15, 2026 HOLD Strong Buy
+11.6% avg upside
19 analysts
 — +6.2%
ORIC
Oric Pharmaceuticals
 Jun 15, 2026 HOLD Strong Buy
+151.2% avg upside
19 analysts
 — +12.6%
IDYA
IDEAYA Biosciences
 Jun 15, 2026 HOLD Strong Buy
+33.7% avg upside
29 analysts
 — +14.6%
ARVN
Arvinas Holding Company
 Jun 15, 2026 HOLD Strong Buy
+248.2% avg upside
27 analysts
 — +7.2%
CTMX
CytomX Therapeutics
 Jun 15, 2026 HOLD Strong Buy
+232.5% avg upside
21 analysts
 — +10.3%
TYRA
Tyra Bioscience
 May 14, 2026 BUY Strong Buy
+45.6% avg upside
17 analysts
$50.00
64.73% Upside
 -20.4%
ALLO
Allogene Therapeutics
 May 14, 2026 BUY Strong Buy
+640.4% avg upside
28 analysts
$7.00
241.47% Upside
 -3.7%
ZNTL
Zentalis Pharmaceuticals
 May 13, 2026 BUY Buy
+277.0% avg upside
16 analysts
$9.00
126.64% Upside
 -16.4%
BBOT
BridgeBio Oncology Therapeutics
 May 13, 2026 BUY Strong Buy
+227.3% avg upside
10 analysts
$22.00
195.68% Upside
 -5.0%
BMEA
Biomea Fusion
 May 13, 2026 BUY Strong Buy
+985.7% avg upside
15 analysts
$9.00
619.93% Upside
 -1.4%
NRIX
Nurix Therapeutics
 May 13, 2026 BUY Strong Buy
+44.1% avg upside
26 analysts
$28.00
45.05% Upside
 +8.7%
RNAC
Cartesian Therapeutics
 May 12, 2026 HOLD Strong Buy
+247.8% avg upside
19 analysts
 — +2.4%
OKUR
OnKure Therapeutics
 May 06, 2026 BUY Buy
+473.8% avg upside
13 analysts
$30.00
591.33% Upside
 -24.3%
REGN
Regeneron
 Apr 30, 2026 BUY Strong Buy
+24.5% avg upside
57 analysts
$865.00
38.70% Upside
 -10.3%
FULC
Fulcrum Therapeutics
 Apr 28, 2026 BUY Hold
+139.0% avg upside
14 analysts
$15.00
298.87% Upside
 -10.1%
AAPG
Ascentage Pharma Group International Unsponsored ADR
 Mar 27, 2026 BUY Strong Buy
+157.5% avg upside
10 analysts
$45.00
163.53% Upside
 -25.2%
ACRV
Acrivon Therapeutics, Inc.
 Nov 14, 2025 BUY Strong Buy
+797.6% avg upside
13 analysts
$8.00
393.81% Upside
 -21.0%
ELTX
Elicio Therapeutics
 May 14, 2025 HOLD Buy
+404.3% avg upside
11 analysts
 — +101.5%
FATE
Fate Therapeutics
 May 14, 2025 HOLD Buy
+535.5% avg upside
31 analysts
 — +97.9%
VOR
Vor Biopharma
 Dec 09, 2024 BUY Buy
+193.5% avg upside
17 analysts
$160.00
1004.91% Upside
 -48.5%
TSE:APS
Aptose Biosciences
 Oct 31, 2023 BUY Strong Buy
+4176.4% avg upside
10 analysts
$21.36
870.69% Upside
 ·
TSE:MDNA
Medicenna Therapeutics Corp
 Aug 14, 2023 BUY Strong Buy
+1151.4% avg upside
9 analysts
$4.27
941.75% Upside
 ·
QTTB
Q32 Bio
 Jul 31, 2023 HOLD Buy
+350.7% avg upside
24 analysts
 — +52.2%
ALP
Alpha Compute
 Mar 02, 2023 BUY Strong Buy
+7927.1% avg upside
6 analysts
$18.00
7045.69% Upside
 ·
CELU
Celularity
 Dec 22, 2022 HOLD Buy
+2190.8% avg upside
6 analysts
 — -84.6%
NKTX
Nkarta
 Dec 22, 2022 HOLD Strong Buy
+563.0% avg upside
16 analysts
 — -15.8%
MRKR
Marker Therapeutics
 Feb 17, 2022 BUY Strong Buy
+1010.5% avg upside
9 analysts
$50.00
3716.79% Upside
 -48.7%
🔒 24 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Matthew Biegler — Frequently Asked Questions
How accurate are Matthew Biegler's stock ratings?
Based on the calls 13Foresight could measure, about 34% of Matthew's ratings were profitable over a one-year hold, with an average return of -3.0% per rating, or -96.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Matthew ranked on 13Foresight?
Matthew Biegler is currently ranked #2372 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matthew cover?
Matthew most recently has ratings on GILD, OLMA, RLAY, ORIC, IDYA, ARVN, CTMX, TYRA, ALLO, ZNTL, BBOT, BMEA and 17 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.